101 related articles for article (PubMed ID: 35304155)
1. N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial.
Sarris J; Byrne G; Castle D; Bousman C; Oliver G; Cribb L; Blair-West S; Brakoulias V; Camfield D; Ee C; Chamoli S; Boschen M; Dean OM; Dowling N; Menon R; Murphy J; Metri NJ; Nguyen TP; Wong A; Jordan R; Karamacoska D; Rossell SL; Berk M; Ng CH
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jul; 117():110550. PubMed ID: 35304155
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
3. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH
CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
[TBL] [Abstract][Full Text] [Related]
4. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
[No Abstract] [Full Text] [Related]
5. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
[TBL] [Abstract][Full Text] [Related]
6. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial.
Bloch MH; Panza KE; Yaffa A; Alvarenga PG; Jakubovski E; Mulqueen JM; Landeros-Weisenberger A; Leckman JF
J Child Adolesc Psychopharmacol; 2016 May; 26(4):327-34. PubMed ID: 27027204
[TBL] [Abstract][Full Text] [Related]
7. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol.
Maier A; Dharan A; Oliver G; Berk M; Redston S; Back SE; Kalivas P; Ng C; Kanaan RA
BMC Psychiatry; 2020 Aug; 20(1):397. PubMed ID: 32762663
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial.
Ghanizadeh A; Mohammadi MR; Bahraini S; Keshavarzi Z; Firoozabadi A; Alavi Shoshtari A
Iran J Psychiatry; 2017 Apr; 12(2):134-141. PubMed ID: 28659986
[No Abstract] [Full Text] [Related]
10. "N-Acetylcysteine for Obsessive-Compulsive and Related Disorders in Children and Adolescents: A Review".
Parli GM; Gales MA; Gales BJ
Ann Pharmacother; 2023 Jul; 57(7):847-854. PubMed ID: 36384314
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive-compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study.
Westwell-Roper C; Best JR; Elbe D; MacFadden M; Baer S; Tucker L; Au A; Naqqash Z; Lin B; Lu C; Stewart SE
BMJ Open; 2022 Jan; 12(1):e054296. PubMed ID: 35105633
[TBL] [Abstract][Full Text] [Related]
12. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-Acetylcysteine for treatment-resistant PTSD.
Kanaan RA; Oliver G; Dharan A; Sendi S; Maier A; Mohebbi M; Ng C; Back SE; Kalivas P; Berk M
Psychiatry Res; 2023 Sep; 327():115398. PubMed ID: 37540942
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.
Berk M; Dean OM; Cotton SM; Jeavons S; Tanious M; Kohlmann K; Hewitt K; Moss K; Allwang C; Schapkaitz I; Robbins J; Cobb H; Ng F; Dodd S; Bush AI; Malhi GS
J Clin Psychiatry; 2014 Jun; 75(6):628-36. PubMed ID: 25004186
[TBL] [Abstract][Full Text] [Related]
14. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
Murphy TK; Brennan EM; Johnco C; Parker-Athill EC; Miladinovic B; Storch EA; Lewin AB
J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):640-651. PubMed ID: 28358599
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory obsessive-compulsive disorder with nutraceuticals (TRON): a 20-week, open label pilot study.
Sarris J; Byrne GJ; Oliver G; Cribb L; Blair-West S; Castle D; Dean OM; Camfield DA; Brakoulias V; Bousman C; Dowling N; Ee C; Murphy J; Menon R; Berk M; Chamoli S; Boschen M; Ng CH
CNS Spectr; 2022 Oct; 27(5):588-597. PubMed ID: 34165060
[TBL] [Abstract][Full Text] [Related]
16. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo.
Berk M; Turner A; Malhi GS; Ng CH; Cotton SM; Dodd S; Samuni Y; Tanious M; McAulay C; Dowling N; Sarris J; Owen L; Waterdrinker A; Smith D; Dean OM
BMC Med; 2019 Jan; 17(1):18. PubMed ID: 30678686
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness, cost-effectiveness and acceptability of low-intensity interventions in the management of obsessive-compulsive disorder: the Obsessive-Compulsive Treatment Efficacy randomised controlled Trial (OCTET).
Lovell K; Bower P; Gellatly J; Byford S; Bee P; McMillan D; Arundel C; Gilbody S; Gega L; Hardy G; Reynolds S; Barkham M; Mottram P; Lidbetter N; Pedley R; Molle J; Peckham E; Knopp-Hoffer J; Price O; Connell J; Heslin M; Foley C; Plummer F; Roberts C
Health Technol Assess; 2017 Jun; 21(37):1-132. PubMed ID: 28681717
[TBL] [Abstract][Full Text] [Related]
19. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.
McDougle CJ; Goodman WK; Leckman JF; Lee NC; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Apr; 51(4):302-8. PubMed ID: 8161290
[TBL] [Abstract][Full Text] [Related]
20. Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial.
Grant JE; Hook R; Valle S; Chesivoir E; Chamberlain SR
Int Clin Psychopharmacol; 2021 Sep; 36(5):225-229. PubMed ID: 34310432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
